DDInter458 DDInter1409
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Cyclosporine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is upregulated by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Cyclosporine {u} (Compound) upregulates {v} (Gene) CCDC92
CCDC92 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDC25B
CDC25B {u} (Gene) is upregulated by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDC25B
CDC25B {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Cyclosporine {u} (Compound) upregulates {v} (Gene) HDAC6
HDAC6 {u} (Gene) is downregulated by {v} (Compound) Bupropion
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Zidovudine
Zidovudine {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Cyclosporine {u} (Compound) downregulates {v} (Gene) AURKA
AURKA {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Cyclosporine {u} (Compound) downregulates {v} (Gene) SDHB
SDHB {u} (Gene) is downregulated by {v} (Compound) Bupropion
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Cyclosporine {u} (Compound) downregulates {v} (Gene) HDAC2
HDAC2 {u} (Gene) is bound by {v} (Compound) Valproic acid
Valproic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Cyclosporine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cyclosporine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cyclosporine (Compound) upregulates CCDC92 (Gene) and CCDC92 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cyclosporine (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is upregulated by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cyclosporine (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cyclosporine (Compound) upregulates HDAC6 (Gene) and HDAC6 (Gene) is downregulated by Bupropion (Compound) and Bupropion may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Cyclosporine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Zidovudine (Compound) and Zidovudine may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Cyclosporine (Compound) downregulates AURKA (Gene) and AURKA (Gene) is bound by Crizotinib (Compound) and AURKA (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cyclosporine (Compound) downregulates SDHB (Gene) and SDHB (Gene) is downregulated by Bupropion (Compound) and Bupropion may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Cyclosporine (Compound) downregulates HDAC2 (Gene) and HDAC2 (Gene) is bound by Valproic acid (Compound) and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a